Keros Therapeutics has raised $23m in a series B funding round.

Existing investors Pontifax, Arkin Bio Ventures, Partners Innovation Fund, and Medison Pharma participated in the funding round along with new investor Global Health Sciences Fund.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new investment has raised the company’s total venture funding to $34m.

Proceeds will be utilised to progress Keros’ two lead drug candidates into clinical trials.

Keros Therapeutics is a pharmaceutical company based in the US.

Axsome Therapeutics has raised $23.3m by selling 2.8 million shares under an existing at-the-market (ATM) facility signed with Leerink Partners.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It will use the proceeds to develop novel therapies for central nervous system disorders and perform ongoing clinical trials of drug candidates as well as support future clinical programmes.

Axsome is a biopharmaceutical company, while Leerink Partners is a healthcare-focused investment bank.

“Axsome Therapeutics has raised $23.3m by selling 2.8 million shares under an existing at-the-market facility signed with Leerink Partners.”

Both the companies involved in the transaction are based in the US.

Stelexis Therapeutics has secured $43m in a series A funding round.

The company will use the proceeds to further develop its novel proprietary platform to discover and develop cancer therapeutics.

This platform will identify the pre-cancerous stem cells that lead to malignant tumour formation and cancer relapse.

Stelexis is a biopharmaceutical company based in the US.

Apollomics has raised $100m in a series B funding round led by CMB International.

Existing investor OrbiMed Asia and several new investors also participated in the round.

The proceeds will be used towards the development of new candidates and for advancing existing oncology programmes.

Apollomics is an American biopharmaceutical company.

CANbridge Pharmaceuticals has signed a licensing agreement with GC Pharma to commercialise Hunterase™ in China.

Hunterase™ is a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy indicated for the treatment of Hunter syndrome.

CANbridge and GC Pharma are biopharmaceutical companies based in China and South Korea respectively.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact